Ordaōs/NonExomics Deal Shines Light on Novel Mini-Proteins

Ordaōs and NonExomics announced a research pact Wednesday to develop mini-proteins, called miniPROs, for three specific difficult-to-target rare cancers.

In an interview with BioSpace, Ordaōs CEO David Longo indicated the research collaboration’s focus is on rare cancers, that the commonality is “difficult targets” and that the miniPROs™ are “uniquely capable of being inserted into the tumor microenvironments.”